纤溶酶治疗结核性胸膜炎胸膜肥厚的效果研究

摘要

Objective To explore plasmin treatment effect to patients with pleural thickening of tuberculosis pleurisy. Methods Choose 36 patients with pleural thickening of tuberculosis pleurisy who are treated in hospital from July 2013 to September 2014 and separate them into groups at random;18 patients in study group are given plasmin treatment in addition to elementary treatment,while 18 patients in control group are given conventional anti-tuberculosis medication treatment,and then compare patients’symptom improvement as wel as side-effect conditions between two groups. Results There is no side effect to be seen in study group and treatment efficacy in study group is 94.44%,while,side-effect incidence in control group is 16.7% and treatment efficacy in control group is 77.78%;there is a treatment differential between two groups,and such a differential has statistic value(P<0.05). Conclusion Plasmin treatment is of efficacy in treatment of pleural thickening of tuberculosis pleurisy;it is of efficacy and medication safety to relieve patients’symptoms and improve patients’quality of life;thus,such an effective treatment is quite worthwhile to be promoted widespread.%目的：探究结核性胸膜炎胸膜肥厚患者采用纤溶酶的治疗效果。方法选取2013年7月～2014年9月收治的36例结核性胸膜炎胸膜肥厚患者进行治疗，随机分组，实验组18例患者在基础治疗的同时使用纤溶酶这种药物，对照组18例患者仅给予常规抗结核治疗，对比患者症状的改善和不良反应。结果实验组患者没有出现不良反应，治疗总显效率为94.44%，对照组患者不良反应发生率为16.7%，治疗总显效率为77.78%。两组患者的治疗效果差异较为显著，有统计学意义（P<0.05）。结论结核性胸膜炎胸膜肥厚患者采用纤溶酶的治疗，可加快症状的缓解，效果显著，提高生活质量，且药物的安全性较高，值得推荐。